<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nierengarten, Mary Beth</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Consistent Targeted Dosing of BUD Benefits Asthma Patients Needing Long-Term Oral Corticosteroids</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with severe asthma who depend on long-term oral corticosteroid therapy, additional treatment with consistent doses of budesonide (BUD) delivered by a novel inhalation system significantly improved lung function and control of asthma exacerbations. This article discusses outcomes from the AKITA Inhaled Steroid Suspension for Inhalation in Subjects With Asthma [AICS; NCT01200108; Canisius S et al. Am J Respir Crit Care 2014]</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>